Skip to main content

Other drugs used in diabetes

Monoclonal antibody model

10-23-2023 | Type 1 diabetes | News

Teplizumab may PROTECT β-cell function in youth with newly diagnosed type 1 diabetes

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

09-12-2023 | Type 1 diabetes | News

Preservation of β-cell function with teplizumab in type 1 diabetes confirmed

Teplizumab consistently preserves the function of β-cells in people with type 1 diabetes as measured by higher C-peptide levels at 1 and 2 years post-treatment.

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

05-26-2023 | Type 2 diabetes | News

Common antidiabetic add-on therapies offer similar renal outcomes

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

11-18-2022 | Teplizumab | News

FDA clearance for teplizumab to slow type 1 diabetes onset

Click through to read more on this announcement

11-07-2022 | Lipid-lowering medications | News

Pemafibrate disappoints in high-risk type 2 diabetes

Treatment with pemafibrate does not reduce the risk for cardiovascular events in people with type 2 diabetes, despite substantial reductions in triglycerides, report the PROMINENT trial investigators.

10-13-2022 | Anti-hypertensive medications | News

TIME of antihypertensive administration ‘should be shared decision’

The TIME study finds no difference between morning and evening administration of antihypertensive medications in terms of preventing major adverse cardiovascular events.

Doctor measuring arterial blood pressure on arm of a patient

07-28-2022 | Anti-hypertensive medications | News

No justification for bespoke antihypertensive intervention in type 2 diabetes

The absolute benefit of blood pressure reduction on cardiovascular risk does not differ according to whether or not people have type 2 diabetes, shows an individual participant data meta-analysis.